Get the Stockscreener App
118.86
1.28%
1.50
Mirum Pharmaceuticals Inc stock is traded at $118.86, with a volume of 435.86K.
It is up +1.28% in the last 24 hours and up +16.48% over the past month.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
See More
Previous Close:
$117.36
Open:
$115.425
24h Volume:
435.86K
Relative Volume:
0.45
Market Cap:
$7.25B
Revenue:
$569.61M
Net Income/Loss:
$-23.36M
P/E Ratio:
-8.7369
EPS:
-13.6043
Net Cash Flow:
$54.87M
1W Performance:
-2.68%
1M Performance:
+16.48%
6M Performance:
+30.54%
1Y Performance:
+125.41%
1-Day Range:
$113.00
$119.57
1-Week Range:
$113.00
$121.81
52-Week Range:
$50.25
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
118.86 | 7.16B | 569.61M | -23.36M | 54.87M | -13.60 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Citizens reiterates Mirum Pharmaceuticals stock rating on revenue outlook By Investing.com - Investing.com Canada
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Arcutis Expands Board of Directors with Appointment of Chris Peetz - GlobeNewswire Inc.
MIRM5806400 Bond Risk Profile - TradingView
US604749AB7 Bond Coupon Profile — Rate & Payments - TradingView
US604749AB7 Bond Profile — Key Metrics - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Insider Sell Alert: Eric Bjerkholt Sells 5,000 Shares of Mirum P - GuruFocus
Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing - Moomoo
Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing - Moomoo
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock - Investing.com
Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock - Investing.com
Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock By Investing.com - Investing.com India
Mirum Pharmaceuticals (MIRM) CEO sells 20,000 shares after exercising options - Stock Titan
Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares under 10b5-1 plan - Stock Titan
Why (MIRM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Mirum Pharmaceuticals outlines its liver disease focus as shares trade on Nasdaq - AD HOC NEWS
RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating - marketscreener.com
Christopher Peetz plans 20,000-share sale (NASDAQ: MIRM) - Stock Titan
Eric Bjerkholt reports sale of 5,000 MIRM shares (MIRM) - Stock Titan
Enterprise value to EBIT forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio - Seeking Alpha
MIRMMirum Pharmaceuticals Inc Latest SEC Filings - Finviz
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM) - GuruFocus
Mirum Pharmaceuticals SVP sells $326,520 in common stock By Investing.com - Investing.com South Africa
Form 4 Mirum Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
Mirum Pharmaceuticals SVP sells $326,520 in common stock - Investing.com
Mirum Pharmaceuticals (MIRM) SVP Howe sells 2,721 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD - Investing.com
J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125 - Moomoo
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib - Yahoo Finance
Form 144 MIRUM PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada
2,721 performance shares proposed; Jolanda Howe sold 2,594 (MIRM) - Stock Titan
Mirum Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Fischer Laurent - Moomoo
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength? - Yahoo Finance
5 Biotech Stocks That Skyrocketed 105% To 235% — TWST, INDV, MIRM & More - RTTNews
Mirum Pharmaceuticals Stock Surges 25%, With A 9-Day Winning Spree - Trefis
Enterprise value to EBITDA forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Price to book forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Mirum and Incyte's zilurgisertib shows positive phase 2 data in FOP - MSN
Enterprise value to revenue forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Price to sales forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Price to earnings forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Understanding Momentum Shifts in (MIRM) - Stock Traders Daily
Price to earnings forward of Mirum Pharmaceuticals, Inc. – HAM:08D - TradingView
9-Day Rally Sends Mirum Pharmaceuticals Stock Up 25% - Trefis
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):